The Indian Journal of Pediatrics

, Volume 80, Issue 8, pp 655–658 | Cite as

Effect of Deferasirox Chelation on Liver Iron and Total Body Iron Concentration

  • Javed Ahmed
  • Noor Ahmad
  • Bhavin Jankharia
  • Pradeep Krishnan
  • Rashid H. Merchant
Original Article

Abstract

Objective

To determine efficacy of Deferasirox (DFX) on total body iron and liver iron concentration (LIC) as estimated by serum ferritin (SF) and liver MRI T2*.

Methods

Thirty patients had baseline MRI T2* of the liver performed to determine LIC before starting DFX therapy and classified as normal >6.3 milliseconds (ms), mild 6.3−2.7 ms, moderate 2.7−1.4 ms and severe iron overload <1.4 ms. DFX was given 25–35 mg/kg/d. The serum ferritin (SF) level was estimated every 3 monthly. Liver iron is expressed as liver R2* = 1000/T2*. The primary end point of the study was to determine change in SF and liver MRI R2* values after 18 mo of therapy.

Results

All 30 patients had some degree of liver iron overload; 11 (36.6 %) had severe, 15 (50 %) had moderate while 4 (13.3 %) had mild overload. The pre-DFX therapy median SF of all was 3604.5 ng/mL (IQR 2357.0–5056.0) and median liver R2* was 574.71 Hz (IQR 411.3–770.8). After 18 mo, SF dropped significantly to a median of 2036.5 ng/mL (IQR 1700.0–3162.0) (p = 0.0011), while median liver R2* decreased from 574.71 to 568.18Hz (IQR 393.4–803.2) which was not significant (p = 0.986).

Conclusions

DFX monotherapy at the doses used decreases total body iron, but does not significantly decrease liver iron. It is well tolerated by Indian thalassemia patients, with observed side effects including rash, diarrhea, and transient albuminuria. MRI T2* (and derived R2*) can serve as useful method in non invasive monitoring of LIC in thalassemia patient management.

Keywords

Thalassemia Liver iron concentration Liver MRI T2*/R2* Serum ferritin Deferasirox 

Notes

Acknowledgments

The authors are thankful to Dr. Deepak Langde for his inputs and analysis of statistical data and Mrs. Gracy Simond (Nurse Incharge of Thalassemia Transfusion Centre Nanavati Hospital) for maintaining data and nursing care of their patients.

Contributions

RHM conceptualized the study and was principal investigator. JA is responsible for data collection, monitoring and along with NA for manuscript write-up. BJ and PK are the radiologists reporting MRI T2*and contributed to the manuscript.

Conflict of Interest

None.

Role of Funding Source

None.

References

  1. 1.
    Borgda-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–93.Google Scholar
  2. 2.
    Angelucci E, Brittenham GM, Mclaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343:327–31.PubMedCrossRefGoogle Scholar
  3. 3.
    Tziomalos K, Perifanis V. Liver iron content determination by magnetic resonance imaging. World J Gastroenterol. 2010;16:1587–97.PubMedCrossRefGoogle Scholar
  4. 4.
    Wood JC. Diagnosis and management of transfusion iron overload: The role of imaging. Am J Hematol. 2007;82:1132–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Butensky E, Fischer R, Hudes M, et al. Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am J Clin Pathol. 2005;123:146–52.PubMedCrossRefGoogle Scholar
  6. 6.
    Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876–84.PubMedCrossRefGoogle Scholar
  7. 7.
    Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: Impact of total body iron stores. Blood. 2010;116:537–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Di Tucci AA, Matta G, Deplano S, et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica. 2008;93:1385–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Wood JC. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol. 2007;14:183–90.PubMedCrossRefGoogle Scholar
  10. 10.
    Perifanis V, Tziomalos K, Tsatra I, Karyda S, Patsiaoura K, Athanassiou-Metaxa M. Prevalence and severity of liver disease in patients with b thalassemia major. A single-institution fifteen-year experience. Haematologica. 2005;90:1136–8.PubMedGoogle Scholar
  11. 11.
    Jean G, Terzoli S, Mauri R, et al. Cirrhosis associated with multiple transfusions in thalassaemia. Arch Dis Child. 1984;59:67–70.PubMedCrossRefGoogle Scholar
  12. 12.
    Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron–overloaded patients with beta-thalassemia: The ESCALATOR study. Eur J Haematol. 2009;82:458–65.PubMedCrossRefGoogle Scholar
  13. 13.
    Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Mazza P, Giua R, De Marco S, et al. Iron overload in thalassemia: Comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver. Haematologica. 1995;80:398–404.PubMedGoogle Scholar
  15. 15.
    Merchant R, Joshi A, Ahmed J, Krishnan P, Jankharia B. Evaluation of cardiac iron load by cardiac magnetic resonance in thalassemia. Indian Pediatr. 2011;48:697–701.PubMedCrossRefGoogle Scholar
  16. 16.
    Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112:2973–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147:752–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overload patients with sickle cell disease. Br J Haematol. 2011;154:387–97.PubMedCrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2013

Authors and Affiliations

  • Javed Ahmed
    • 1
  • Noor Ahmad
    • 3
  • Bhavin Jankharia
    • 4
  • Pradeep Krishnan
    • 4
  • Rashid H. Merchant
    • 1
    • 2
  1. 1.Department of PediatricsDr. Balabhai Nanavati HospitalMumbaiIndia
  2. 2.MumbaiIndia
  3. 3.Dr. D.Y. Patil Medical CollegeMumbaiIndia
  4. 4.Department of RadiologyPiramal Jhankaria Imaging and DiagnosticsMumbaiIndia

Personalised recommendations